Thus, in metastatic RCC, the role of PD-L1 as a predictive or prognostic marker is unclear. We reviewed the ICIs in first-line renal cancer trials to evaluate if PD-L1 expression matters (Table 1). This evidence concerns the gene CD274 and renal carcinoma.